FIELD: pharmaceutical industry.
SUBSTANCE: invention provides therapeutical formulation for improving fertility and treating sterility caused by polycystic ovary syndrome, which composition is characterized by that formulation thereof involves use of dipeptidylpeptidase IV inhibitor. Treatment of polycystic ovary syndrome-caused sterility is high successful with effective active ingredient concentration equal to 1 μM. When dipeptidylpeptidase IV inhibitor is administered, luteinizing hormone and testosterone levels in blood are normalized. Claimed compounds are low toxic for warm-blooded animals and humans.
EFFECT: widened choice of efficient antisterility drugs.
7 cl, 3 ex
Authors
Dates
2005-02-27—Published
2000-03-21—Filed